Help improve early cancer detection - join the PATHFINDER 2 study
Too often, cancer goes undetected until it is at an advanced stage. Thinking about the possibility of having cancer can feel overwhelming, but taking steps to find cancer early can help you feel more in control of your health. The earlier that cancer is found, the higher the chance of survival.
The PATHFINDER 2 Study will evaluate the performance of a multi-cancer early detection test, called Galleri, that can detect many types of cancer through a simple blood draw. This test is being studied and is not approved or cleared by the Food and Drug Administration (FDA). It is not meant to replace the cancer screening tests your healthcare provider may recommend, such as colonoscopy or mammography.
When cancers are diagnosed early before they have had the chance to spread, the overall 5-year survival rate is 4 times higher than when diagnosed in later stages.
- Read and sign an informed consent form that fully explains the study
- Provide your medical history and allow access to your medical records
- Have a blood sample (40 mL) drawn by a trained practitioner
- Complete questionnaire(s) at different time intervals
The PATHFINDER 2 Study is currently open to men and women aged 50 years or older who meet eligibility criteria and receive care at participating health systems. Participants in previous or ongoing GRAIL sponsored studies are not eligible to participate in the PATHFINDER 2 Study.
If you are interested in enrolling or have additional questions, contact our Clinical Trials Office team by calling (804) 628-6430, send an email to masseycpc@vcu.edu or complete the form below.
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 years or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “Cancer Signal Not Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures such as X-Rays or imaging, endoscopy or biopsy to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur.
All cells in your body release DNA into the bloodstream. DNA from cancer cells is different than DNA from healthy cells. The Galleri test looks for signals present in the blood that may be associated with cancer at the time of your blood draw. This test does not measure your genetic risk of developing cancer in the future.
Have questions? Want to enroll?
If you would like to enroll in the PATHFINDER 2 trial, or have any additional questions, please complete the form below and a study team member will contact you as soon as possible.